Table 4 Baseline features of the studies
Trials | Age (yrs) | Males (%) | HTN (%) | DSL (%) | DM (%) | CS (%) |
|---|---|---|---|---|---|---|
P/C | P/C | P/C | P/C | P/C | Â | |
INFUSE AMI | 57.6/62.7 | 79.4/71.0 | 24.5/35.0 | 16.8/15.2 | 9.70/12.1 | 68.8/56.3 |
JUMBO TIMI 26 | 59.0/58.0 | 76.3/77.0 | – | – | 27.5/25.0 | 23.3/31.0 |
PRASFIT ACS | 65.4/65.1 | 78.2/79.4 | 72.3/72.4 | 75.3/73.7 | 36.5/35.0 | 39.9/41.2 |
PRINCIPLE TIMI 44 | 64.0/63.8 | 71.6/77.8 | 85.3/77.8 | 90.2/86.9 | 32.4/29.3 | 17.6/16.2 |
TAILOR | 63.0/63.0 | 74.1/82.7 | 74.1/82.7 | 83.3/88.5 | 29.6/34.6 | 77.8/67.3 |
TRANSLATE ACS | 56.0/61.0 | 78.1/69.4 | 61.7/69.1 | – | 24.5/27.0 | 40.4/38.6 |
TRIGGER PCI | 65.8/66.3 | 72.2/73.0 | 88.7/89.1 | – | 41.0/42.7 | 16.2/14.0 |
TRITON TIMI 38 | 58.0/59.0 | 79.0/76.0 | 49.0/50.0 | 41.0/41.0 | 19.0/19.0 | 47.0/44.0 |